Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON).
AstraZeneca
324 participants
Aug 3, 2022
INTERVENTIONAL
Conditions
Summary
Clinical study to investigate the efficacy and safety of savolitinib in combination with osimertinib versus platinum-based doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed on treatment with Osimertinib.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
300 mg savolitinib (3 × 100 mg tablets twice daily) Administrative route : oral
80 mg osimertinib (1 × 80 mg tablet once daily) Administrative route : oral
Pemetrexed (500 mg/m2) Administrative route : IV infusion
Cisplatin (75 mg/m2) or Administrative route : IV infusion
Carboplatin (AUC5) Administrative route : IV infusion
Locations(283)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05261399